Published 14 hours ago • loading... • Updated 14 hours ago

Genomics Launches the Mystra AI Platform, Adopted by Industry Giants and Up-and-Coming Biotechs

On Tuesday, June 2, 2026, LONDON-based Techbio company Genomics launched The Mystra, an agentic AI platform designed to accelerate drug target discovery and validation using vast human genetics datasets.
The pharmaceutical industry faces a severe productivity crisis, with 95% of drug candidates failing in clinical trials and pushing development costs beyond $2.3 billion; Genomics addresses this by leveraging over 45,000 GWAS to identify targets 2.6 times more likely to succeed.
Collaborating with over 60 Statistical Genetics scientists, the platform provides transparent, reproducible insights; Amazon Web Services Chief Medical Officer Rowland Illing stated it will "change the way diseases and targets are identified," enabling PhD-level work in minutes.
Industry leaders have rapidly adopted The Mystra into research workflows; BridgeBio Pharma Associate Director Xue Zeng reported it "accelerates our day-to-day workflow," while Novo Nordisk Global Vice President Mishal Patel cited partnership benefits over internal development.
BioIndustry Association Chief Executive Officer Professor Chris Molloy stated the release demonstrates Britain's ability to harness genomic data globally, marking the start of a new era of genomic intelligence with world-class pace and scale.

Insights by Ground AI